Literature DB >> 33997945

Enhancing Mood, Cognition, and Quality of Life in Pediatric Multiple Sclerosis.

Cristina Fernandez-Carbonell1, Leigh E Charvet2, Lauren B Krupp2.   

Abstract

Pediatric-onset multiple sclerosis (POMS), representing approximately 5% of all MS cases, affects the central nervous system during its ongoing development. POMS is most commonly diagnosed during adolescence but can occur in younger children as well. For pediatric patients with MS, it is critical to manage the full impact of the disease and monitor for any effects on school and social functioning. Disease management includes not only disease-modifying therapies but also strategies to optimize wellbeing. We review the interventions with the highest evidence of ability to improve the disease course and quality of life in POMS. High levels of vitamin D and a diet low in saturated fat are associated with lower relapse rates. Exercise ameliorates fatigue and sleep. Behavioral strategies for sleep hygiene and mood regulation can also improve fatigue and perceived health. POMS management should be addressed holistically, including assessing overall symptom burden as well as the psychological and functional impact of the disease.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Year:  2021        PMID: 33997945     DOI: 10.1007/s40272-021-00451-5

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  131 in total

1.  Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network.

Authors:  L E Charvet; E H O'Donnell; A L Belman; T Chitnis; J M Ness; J Parrish; M Patterson; M Rodriguez; E Waubant; B Weinstock-Guttman; L B Krupp
Journal:  Mult Scler       Date:  2014-03-31       Impact factor: 6.312

2.  Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years.

Authors:  L A Benson; B C Healy; M P Gorman; N F Baruch; T Gholipour; A Musallam; T Chitnis
Journal:  Mult Scler Relat Disord       Date:  2013-07-12       Impact factor: 4.339

Review 3.  Pediatric multiple sclerosis: pathobiological, clinical, and magnetic resonance imaging features.

Authors:  Leonard H Verhey; Manohar Shroff; Brenda Banwell
Journal:  Neuroimaging Clin N Am       Date:  2013-01-21       Impact factor: 2.264

4.  Multiple sclerosis in childhood: clinical features of 149 cases.

Authors:  A Ghezzi; V Deplano; J Faroni; M G Grasso; M Liguori; G Marrosu; C Pozzilli; I L Simone; M Zaffaroni
Journal:  Mult Scler       Date:  1997-02       Impact factor: 6.312

5.  Early onset multiple sclerosis: a longitudinal study.

Authors:  A Boiko; G Vorobeychik; D Paty; V Devonshire; D Sadovnick
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

6.  Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States.

Authors:  T Chitnis; B Glanz; S Jaffin; B Healy
Journal:  Mult Scler       Date:  2009-03-19       Impact factor: 6.312

7.  Long-term outcome of paediatric-onset multiple sclerosis: a population-based study.

Authors:  Katharine E Harding; Kate Liang; Mark D Cossburn; Gillian Ingram; Claire L Hirst; Trevor P Pickersgill; Johann Te Water Naude; Mark Wardle; Yoav Ben-Shlomo; Neil P Robertson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-11-15       Impact factor: 10.154

8.  Improved relapse recovery in paediatric compared to adult multiple sclerosis.

Authors:  Tanuja Chitnis; Greg Aaen; Anita Belman; Leslie Benson; Mark Gorman; Manu S Goyal; Jennifer S Graves; Yolanda Harris; Lauren Krupp; Timothy Lotze; Soe Mar; Jayne Ness; Mary Rensel; Teri Schreiner; Jan-Mendelt Tillema; Emmanuelle Waubant; Bianca Weinstock-Guttman; Shelly Roalstad; John Rose; Howard L Weiner; T Charles Casper; Moses Rodriguez
Journal:  Brain       Date:  2020-09-01       Impact factor: 13.501

9.  Long-term disability progression of pediatric-onset multiple sclerosis.

Authors:  Kyla A McKay; Jan Hillert; Ali Manouchehrinia
Journal:  Neurology       Date:  2019-05-15       Impact factor: 9.910

10.  Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.

Authors:  Emmanuelle Waubant; Brenda Banwell; Evangeline Wassmer; Maria-Pia Sormani; Maria-Pia Amato; Rogier Hintzen; Lauren Krupp; Kevin Rostásy; Silvia Tenembaum; Tanuja Chitnis
Journal:  Neurology       Date:  2019-05-01       Impact factor: 9.910

View more
  1 in total

1.  Reduction in Fatigue Symptoms Following the Administration of Nutritional Supplements in Patients with Multiple Sclerosis.

Authors:  Pasquale Ferorelli; Francesco Antonelli; Anna Shevchenko; Carlo Mischiati; Manfred Doepp; Stefano Lenzi; Ilaria Borromeo; Giordana Feriotto; Simone Beninati
Journal:  Med Sci (Basel)       Date:  2021-07-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.